by Circulating cell-free tumor DNA (ctDNA) refers to fragments of tumor DNA circulating freely in the bloodstream outside of cells. ctDNA is released into the bloodstream from tumor cells as they undergo cell death processes such as apoptosis or necrosis. ctDNA can potentially be used as a biomarker for the early detection of cancers as well as to monitor tumor dynamics and guide precision medicine approaches for cancer treatment.
The global circulating cell-free tumor DNA Market is estimated to be valued at US$ 6.1 Bn in 2023 and is expected to exhibit a CAGR of 6.4% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market Dynamics
Early Cancer Screening: Early detection of cancer improves clinical outcomes and survival rates. ctDNA shows promise for noninvasive cancer screening and early detection. In early-stage cancers, ctDNA levels in the blood can be very low, requiring highly sensitive assays. However, technological advancements are enabling the development of assays with increased sensitivity to detect ctDNA from early-stage cancers. This is expected to increase the clinical adoption of ctDNA-based early cancer screening tests in the coming years. Treatment Monitoring: ctDNA analysis allows real-time monitoring of tumor burden during treatment and follow-up without the need for invasive tumor tissue biopsies. It can detect residual disease earlier than imaging-based methods and help guide treatment decisions. ctDNA levels correlate well with tumor size and response to therapy. Hence, ctDNA is increasingly being used to monitor treatment response and detect relapse or resistance development. This is driving the demand for ctDNA analysis in precision oncology settings.
Segment Analysis
The global circulating cell-free tumor DNA market can be segmented based on sample source, technology, application, end user, and region. The liquid biopsy segment dominates the market as it is minimally invasive and provides real-time tumor mutational burden. This helps in determining personalized treatment with minimal risk and discomfort to the patient.
PEST Analysis
Political: Governments across countries are increasingly funding research activities for developing innovative circulating tumor DNA testing technologies.
Economic: Rising healthcare expenditure and increasing demand for non-invasive diagnostic technologies are fueling the market growth.
Social: Growing awareness about early cancer detection and available treatment options is positively impacting the market.
Technological: Advancements in next-generation sequencing and liquid biopsy technologies have improved the accuracy and efficacy of circulating tumor DNA testing.
Key Takeaways
The Global Circulating Cell-Free Tumor DNA Market Growth is expected to witness high over the forecast period of 2023 to 2030. The global circulating cell-free tumor DNA Market is estimated to be valued at US$ 6.1 Bn in 2023 and is expected to exhibit a CAGR of 6.4% over the forecast period 2023 to 2030.
North America dominates the market currently owing to the presence of advanced healthcare infrastructure and favorable reimbursement policies. Asia Pacific is expected to witness the highest growth rate during the forecast period driven by growing healthcare expenditure, rising cancer incidence, and increasing adoption of advanced cancer diagnostic techniques.
Key players related content comprises Key players operating in the circulating cell-free tumor DNA market are BASF SE, Perstorp Holding AB, Chemoxy International Ltd., and Merck Group. BASF SE offers TruFluor polymers for high-performance coatings with durability, weatherability, and smoothness. Perstorp Holding AB provides specialty esters under the name Novatec that can be used in various applications including food packaging.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
